Clinical Trials

  • Principal Investigator:

    Richard P. Mayeux, MD, MSc
    The goal of this study is to is to focus on the genetic influences on Alzheimers disease (AD) risk. Weare looking for families and/or individuals (affected or unaffected) of any ethic background with a familyhistory of Alzheimer's disease and willing to participate.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to test whether using clindamycin and triamcinolone topical lotions canprevent skin-related side effects of tumor treating fields (TTFields). Clindamycin is an antibiotic. It works by slowing or stopping the growth of bacteria. The FDA has approved the drug for the treatment of various bacterial infections. However, giving clindamycin to people to prevent skin-related side effects of TTFields is an investigational use of the drug. The FDA has not approved this use. Triamcinolone is a corticosteroid. It works by copying the effects of hormones that your body makes...
  • Principal Investigator:

    James M. Noble, MD, MS
    Funded by a multi-year research grant from the National Institute on Aging, the DIAN ObservationalStudy enrolls family members who have parents with a mutated gene known to cause dominantlyinherited Alzheimers (DIAD). Through the study, researchers follow individuals and family members tosee if insights gained could lead to better understanding of how the disease progresses in order toidentify solutions to prevent DIAD or minimize its impact.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo to see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any medication (active ingredient). Researchers use a placebo to see if a study medicine works better or is safer than not taking anything at all.
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    MS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a once time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases.
  • Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on...
  • Principal Investigator:

    Christiane Reitz, MD, PhD
    We are recruiting families or individuals with members above the age of 70 who do not have dementia or are not experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will...
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of the study is to evaluate the tolerability of a ketogenic diet in conjunction with metformin in people with malignant glioma. The study doctors will try to determine if maintaining the ketogenic diet with metformin will have any effect on your tumor.
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    Genes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and test an algorithm predicting risk of MS onset that...
  • Principal Investigator:

    Philip L. De Jager, MD, PHD
    Genes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and test an algorithm predicting risk of MS onset that...

Pages